Russia has said it intends to conduct Phase 3 trials of its already-approved vaccine later this month, but did not provide much additional information. The tests will be conducted in Russia, the United Arab Emirates and Saudi Arabia, according to Kirill Dmitriev, head of the Russian Direct Investment Fund, which is financing the research.
It’s not known what criteria Russian regulators used to judge the performance of the new vaccine. In the U.S., these standards are set by the Food and Drug Administration. The agency has said that any potential coronavirus vaccine will need to be at least 50 percent effective to be approved, which means the vaccine would need to prevent infections in at least 50 percent of the people who receive it.NBC ‘Reckless and foolish’: Why Russia’s vaccine has experts alarmed